Skeletal health in breast cancer survivors

[en] Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sectional studies have reported, nevertheless, that patients with breast cancer have a lower bone mass and potentially a higher incidence of fractures than expected. In any case, it appears that patients with breast cancer are not protected from osteoporosis, which provides further support for the recommendation that bone health is assessed after a diagnosis of breast cancer. Most adjuvant therapies will lead to increased bone loss and a higher fracture rate. Among the adjuvant therapy options for premenopausal patients with breast cancer, endocrine therapy (ovarian suppression) and chemotherapy can result in cancer treatment-induced bone loss (CTIBL) of up to 10% at the lumbar spine after one year. Antiresorptive therapies prevent CTIBL in premenopausal women with breast cancer. Most of the evidence demonstrating the efficacy of bisphosphonates in the prevention of CTIBL is derived from clinical trials with zoledronic acid. The addition of zoledronic acid 4 mg per six months to adjuvant endocrine therapy maintained and even increased bone mass during a 3-year treatment period and significantly improved disease-free survival in a population of young women who underwent menopause due to the adjuvant treatment. The major contributor to bone loss in the adjuvant treatment of breast cancer in postmenopausal women is the use of aromatase inhibitors (AIs). Oncology trials have underestimated the fracture risk in the setting of AI-induced bone loss. In the ABCSG-18 study, the only trial in which fracture incidence was the primary endpoint, the rate of clinical fractures was close to 10% after 3 years in the placebo group on AIs only. Bisphosphonates and denosumab at osteoporosis treatment doses can counteract AI-induced bone loss. In the ABCSG-18 trial, treatment with denosumab 60 mg injection every 6 months reduced the risk of first clinical fracture relative to placebo by 50%. Current guidelines recommend antiresorptive therapy in patients with a baseline T score of<−2.0 or with two or more clinical risk factors for fracture. These recent guidelines will need to be updated, as similar significant protective effects were seen in women with either normal or low bone mass. Moreover, a formal meta-analysis of individual patient data from more than 18,000 women in 26 randomized trials of adjuvant zoledronic acid or clodronate treatment for early breast cancer revealed that bisphosphonates significantly reduced the risk of first distant recurrence in bone and the risk of breast cancer mortality, at least in postmenopausal women. Even though the increased risk of fracture during adjuvant treatment for breast cancer in postmenopausal women is notable, an enhanced risk of fracture in long-term survivors of breast cancer remains under debate. The most recent studies suggest that Caucasian breast cancer survivors do not have a significantly increased risk of osteoporotic fracture over the long term.

Disciplines :

Public health, health care sciences & services
Oncology

Author, co-author :

Bruyère, Olivier ; Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Bergmann, Pierre

CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Service de chimie clinique

Gielen, Evelien

Goemaere, Stefan

Kaufman, Jean-Marc

Rozenberg, Serge

Body, Jean-Jacques

Language :

English

Title :

Skeletal health in breast cancer survivors

Publication date :

2017

Journal title :

Maturitas

ISSN :

0378-5122

eISSN :

1873-4111

Publisher :

Elsevier, Limerick, Ireland

Volume :

105

Pages :

78-82

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 14 September 2017

Statistics

Number of views

71 (6 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, M., Mandelblatt, J.S., Yakovlev, A.Y., Habbema, J.D., Feuer, E.J., Cancer, I., for the Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators, Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353:17 (2005), 1784–1792.
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., Forbes, J.F., A.L. investigators, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11:12 (2010), 1135–1141.
T.A.o.i.C.T.G. Arimidex, Forbes, J.F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J.S., Baum, M., Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9:1 (2008), 45–53.
G. Early Breast Cancer Trialists' Collaborative, Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:10001 (2015), 1341–1352.
Gonnelli, S., Petrioli, R., Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clin. Interv. Aging 3:4 (2008), 647–657.
Mirza, F.S., Management of bone disease in patients undergoing hormonal therapy for breast cancer. Endocrinol. Metab. Clin. North Am. 40:3 (2011), 549–562 (viii).
Tremollieres, F.A., Screening for osteoporosis after breast cancer: for whom, why and when. Maturitas 79:3 (2014), 343–348.
Body, J.J., Increased fracture rate in women with breast cancer: a review of the hidden risk. BMC Cancer, 11, 2011, 384.
Qu, X., Zhang, X., Qin, A., Liu, G., Zhai, Z., Hao, Y., Li, H., Zhu, Z., Dai, K., Bone mineral density and risk of breast cancer in postmenopausal women. Breast Cancer Res. Treat. 138:1 (2013), 261–271.
Olsson, H., Hagglund, G., Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures. Am. J. Epidemiol. 136:4 (1992), 422–427.
Persson, I., Adami, H.O., McLaughlin, J.K., Naessen, T., Fraumeni, J.F. Jr., Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control 5:6 (1994), 523–528.
Servitja, S., Nogues, X., Prieto-Alhambra, D., Martinez-Garcia, M., Garrigos, L., Pena, M.J., de Ramon, M., Diez-Perez, A., Albanell, J., Tusquets, I., Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast 21:1 (2012), 95–101.
Bouvard, B., Hoppe, E., Soulie, P., Georgin-Mege, M., Jadaud, E., Abadie-Lacourtoisie, S., Petit Le Manac'h, A., Laffitte, A., Levasseur, R., Audran, M., Chappard, D., Legrand, E., High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. Ann. Oncol. 23:5 (2012), 1151–1156.
Coleman, R.E., Banks, L.M., Girgis, S.I., Kilburn, L.S., Vrdoljak, E., Fox, J., Cawthorn, S.J., Patel, A., Snowdon, C.F., Hall, E., Bliss, J.M., Coombes, R.C., Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 8:2 (2007), 119–127.
Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J.F., Hoctin-Boes, G., Houghton, J., Locker, G.Y., Tobias, J.S., Group, A.T., Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:9453 (2005), 60–62.
Rabaglio, M., Sun, Z., Price, K.N., Castiglione-Gertsch, M., Hawle, H., Thurlimann, B., Mouridsen, H., Campone, M., Forbes, J.F., Paridaens, R.J., Colleoni, M., Pienkowski, T., Nogaret, J.M., Lang, I., Smith, I., Gelber, R.D., Goldhirsch, A., Coates, A.S., Collaborative, B.I.G., International Breast Cancer Study, G., Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1–98 trial. Ann. Oncol. 20:9 (2009), 1489–1498.
Aebi, S., Davidson, T., Gruber, G., Castiglione, M., E.G.W. Group, Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21:Suppl. 5 (2010), v9–v14.
Vehmanen, L., Elomaa, I., Blomqvist, C., Saarto, T., Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J. Clin. Oncol. 24:4 (2006), 675–680.
Powles, T.J., Hickish, T., Kanis, J.A., Tidy, A., Ashley, S., Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14:1 (1996), 78–84.
Body, J.J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.P., Goemaere, S., Reginster, J.Y., Rozenberg, S., Kaufman, J.M., Management of cancer treatment-induced bone loss in early breast and prostate cancer − a consensus paper of the Belgian Bone Club. Osteoporos. Int. 18:11 (2007), 1439–1450.
Bruning, P.F., Pit, M.J., de Jong-Bakker, M., van den Ende, A., Hart, A., van Enk, A., Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br. J. Cancer 61:2 (1990), 308–310.
Del Mastro, L., Venturini, M., Sertoli, M.R., Rosso, R., Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res. Treat. 43:2 (1997), 183–190.
Hadji, P., Gnant, M., Body, J.J., Bundred, N.J., Brufsky, A., Coleman, R.E., Guise, T.A., Lipton, A., Aapro, M.S., Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?. Cancer Treat. Rev. 38:6 (2012), 798–806.
Shapiro, C.L., Halabi, S., Hars, V., Archer, L., Weckstein, D., Kirshner, J., Sikov, W., Winer, E., Burstein, H.J., Hudis, C., Isaacs, C., Schilsky, R., Paskett, E., Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur. J. Cancer 47:5 (2011), 683–689.
Fogelman, I., Blake, G.M., Blamey, R., Palmer, M., Sauerbrei, W., Schumacher, M., Serin, D., Stewart, A., Wilpshaar, W., Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos. Int. 14:12 (2003), 1001–1006.
Hershman, D.L., McMahon, D.J., Crew, K.D., Shao, T., Cremers, S., Brafman, L., Awad, D., Shane, E., Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J. Clin. Endocrinol. Metab. 95:2 (2010), 559–566.
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., Samonigg, H., Tausch, C., Eidtmann, H., Steger, G., Kwasny, W., Dubsky, P., Fridrik, M., Fitzal, F., Stierer, M., Rucklinger, E., Greil, R., Investigators, A.-T., Marth, C., Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360:7 (2009), 679–691.
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Pristauz, G., Bauernhofer, T., Eidtmann, H., Eiermann, W., Steger, G., Kwasny, W., Dubsky, P., Hochreiner, G., Forsthuber, E.P., Fesl, C., Greil, R., Austrian, B., V.A. Colorectal Cancer Study Group, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12:7 (2011), 631–641.
Hadji, P., Aapro, M.S., Body, J.J., Bundred, N.J., Brufsky, A., Coleman, R.E., Gnant, M., Guise, T., Lipton, A., Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann. Oncol. 22:12 (2011), 2546–2555.
Cuzick, J., Sestak, I., Forbes, J.F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R.E., von Minckwitz, G., Bonanni, B., Palva, T., Howell, A., I.-I. investigators, Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383:9922 (2014), 1041–1048.
Gnant, M., Pfeiler, G., Dubsky, P.C., Hubalek, M., Greil, R., Jakesz, R., Wette, V., Balic, M., Haslbauer, F., Melbinger, E., Bjelic-Radisic, V., Artner-Matuschek, S., Fitzal, F., Marth, C., Sevelda, P., Mlineritsch, B., Steger, G.G., Manfreda, D., Exner, R., Egle, D., Bergh, J., Kainberger, F., Talbot, S., Warner, D., Fesl, C., Singer, C.F., Austrian, B., G. Colorectal Cancer Study, Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:9992 (2015), 433–443.
Coleman, R., Body, J.J., Aapro, M., Hadji, P., Herrstedt, J., E.G.W. Group, Bone health in cancer patients: ESMO clinical practice guidelines. Ann. Oncol. 25:Suppl. 3 (2014), iii124–iii137.
Gielen, E., Bergmann, P., Bruyere, O., Cavalier, E., Delanaye, P., Goemaere, S., Kaufman, J.M., Locquet, M., Reginster, J.Y., Rozenberg, S., Vandenbroucke, A.M., Body, J.J., Osteoporosis in frail patients: a consensus paper of the belgian bone club. Calcif. Tissue Int. 101:2 (2017), 111–131.
Bundred, N.J., Campbell, I.D., Davidson, N., DeBoer, R.H., Eidtmann, H., Monnier, A., Neven, P., von Minckwitz, G., Miller, J.C., Schenk, N.L., Coleman, R.E., Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:5 (2008), 1001–1010.
Early Breast Cancer Trialists' Collaborative, G., Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:10001 (2015), 1353–1361.
Hadji, P., Coleman, R.E., Wilson, C., Powles, T.J., Clezardin, P., Aapro, M., Costa, L., Body, J.J., Markopoulos, C., Santini, D., Diel, I., Di Leo, A., Cameron, D., Dodwell, D., Smith, I., Gnant, M., Gray, R., Harbeck, N., Thurlimann, B., Untch, M., Cortes, J., Martin, M., Albert, U.S., Conte, P.F., Ejlertsen, B., Bergh, J., Kaufmann, M., Holen, I., Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann. Oncol. 27:3 (2016), 379–390.
Utz, J.P., Melton, L.J. 3rd, Kan, S.H., Riggs, B.L., Risk of osteoporotic fractures in women with breast cancer: a population-based cohort study. J. Chron. Dis. 40:2 (1987), 105–113.
Kanis, J.A., McCloskey, E.V., Powles, T., Paterson, A.H., Ashley, S., Spector, T., A high incidence of vertebral fracture in women with breast cancer. Br. J. Cancer 79:7–8 (1999), 1179–1181.
Lamont, E.B., Lauderdale, D.S., Low risk of hip fracture among elderly breast cancer survivors. Ann. Epidemiol. 13:10 (2003), 698–703.
Chen, Z., Maricic, M., Bassford, T.L., Pettinger, M., Ritenbaugh, C., Lopez, A.M., Barad, D.H., Gass, M., Leboff, M.S., Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch. Intern. Med. 165:5 (2005), 552–558.
Melton, L.J. 3rd, Hartmann, L.C., Achenbach, S.J., Atkinson, E.J., Therneau, T.M., Khosla, S., Fracture risk in women with breast cancer: a population-based study. J. Bone Miner. Res. 27:5 (2012), 1196–1205.
Pawloski, P.A., Geiger, A.M., Haque, R., Kamineni, A., Fouayzi, H., Ogarek, J., Petersen, H.V., Bosco, J.L., Thwin, S.S., Silliman, R.A., Field, T.S., Fracture risk in older, long-term survivors of early-stage breast cancer. J. Am. Geriatr. Soc. 61:6 (2013), 888–895.
Hui, S.K., Arentsen, L., Wilcox, A., Shanley, R., Yee, D., Ghebre, R., Spatial and temporal fracture pattern in breast and gynecologic cancer survivors. J. Cancer 6:1 (2015), 66–69.
Colzani, E., Clements, M., Johansson, A.L., Liljegren, A., He, W., Brand, J., Adolfsson, J., Fornander, T., Hall, P., Czene, K., Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br. J. Cancer 115:11 (2016), 1400–1407.
Tsai, C.H., Muo, C.H., Tzeng, H.E., Tang, C.H., Hsu, H.C., Sung, F.C., Fracture in asian women with breast cancer occurs at younger age. PLoS One, 8(9), 2013, e75109.